| Document |
Document Title |
|
WO/2024/107763A1 |
The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-5 methyltransferase and methods of using the same.
|
|
WO/2024/104354A1 |
Provided are a crystal of a substituted piperazine derivative and a preparation method therefor. Specifically, provided are crystal forms A-I of a compound represented by formula (1) and a preparation method therefor.
|
|
WO/2024/103188A1 |
This invention provides compound having the structure of Formula I: (I) and uses of such compounds for modulating Lin28 activity, which may target an interaction site between the Lin28 ZKD and the Let‐7 GGAG motif and prevent Lin28 fro...
|
|
WO/2024/107759A2 |
The present invention provides antibodies that bind specifically to FGFR3 and methods for treating or preventing cancer, such as bladder cancer.
|
|
WO/2024/107494A1 |
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating patients having a HOXB13 genetic variant. In a specific embodiment, a method for identif...
|
|
WO/2024/104416A1 |
The present invention relates to an siRNA and an siRNA conjugate for inhibiting the expression of the sterol regulatory element binding protein cleavage activator protein (SCAP) gene, a pharmaceutical composition comprising same, and use...
|
|
WO/2024/107765A2 |
The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucl...
|
|
WO/2024/106914A1 |
The present invention relates to heteroayl derivatives and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR and/or HER2, which may be usefully employed as a therapeutic ...
|
|
WO/2024/107895A1 |
Provided are methods and dosage regimens for treating cancer using an antibody that specifically binds to human DDR1 and an immune checkpoint inhibitor.
|
|
WO/2024/106941A1 |
The present invention relates to: an expression cassette comprising a polynucleotide that encodes a chimeric antigen receptor effective in cancer treatment; and an effector cell into which the expression cassette is transduced. Particula...
|
|
WO/2024/105197A1 |
The present invention relates to novel pharmaceutical compounds comprising one or more binding molecules (e.g., target protein binders, T) capable of binding to target proteins expressed on tumor cells or on cells present in the tumor mi...
|
|
WO/2024/104425A1 |
The present invention pertains to the technical field of pharmaceuticals and particularly relates to a KRAS inhibitor compound, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention relates to a compo...
|
|
WO/2024/104475A1 |
Disclosed in the present invention are cyclic compounds used as multi-target kinase inhibitors and a preparation method therefor. The multi-target kinase inhibitors of the present invention are represented by general formula I, wherein R...
|
|
WO/2024/107393A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2024/107859A1 |
Substituted cyclopentene-oxymethylene phosphonamidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV- K reverse transcriptase activity, and their use in the treatment...
|
|
WO/2024/105147A1 |
The present specification relates methods of treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic or loco-regionally recurrent breast cancer, comprising administering a next ...
|
|
WO/2024/108131A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I), (II), (III), (IV), (V), or (VI) for killing cancer cell or inhibiting cancer cell proliferation. Further, the compounds and pharmaceutical compositi...
|
|
WO/2024/104304A1 |
Provided in the present invention are a compound as represented by formula (I) and a prodrug thereof, which have a good inhibitory effect on MDM2 and/or MDMX, and can be used for treating MDM2- and/or MDMX-mediated conditions and/or dise...
|
|
WO/2024/108100A1 |
The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
|
|
WO/2024/106866A1 |
The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuat...
|
|
WO/2024/107955A1 |
Disclosed herein is a method of treating breast cancer by administering 8-cyclopentyl- 2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydr
opyrido[2,3-d]pyrimidine-6-carbonitrile, alone or in combination with a second agent such...
|
|
WO/2024/107996A1 |
The present disclosure provides pharmaceutical combinations comprising MetAP2 inhibitors for the treatment of prostate cancer.
|
|
WO/2024/107041A1 |
The invention relates to medicine, and more particularly to oncology, and can be used for treating malignant diseases by the administration of sodium nucleinate in combination with chemoradiotherapy. The method provides an improvement in...
|
|
WO/2024/107959A1 |
Described herein are minimal virus-like particles (mVLPs), comprising a membrane comprising a phospholipid bilayer with one or more ectodomain-truncated VSV envelope glycoproteins on the external side; and a biomolecule cargo disposed in...
|
|
WO/2024/107867A1 |
Provided are methods for treating pancreatic cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).
|
|
WO/2024/108028A1 |
Provided herein are methods of treating a lymphoma in a subject in need thereof by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a second therapeutic agent useful in the treatme...
|
|
WO/2024/103400A1 |
Provided are a polycyclic compound as a GPR75 activator, a pharmaceutical composition comprising same, and use thereof. Specifically, the present invention relates to a compound having a structure of formula (1) or a pharmaceutically acc...
|
|
WO/2024/105364A1 |
The present invention relates to compounds of formula (I). The compounds may be used to inhibit Cdc-Like Kinases, and thereby treat cancer, inflammatory disease, neurodegenerative disease, infection, tendinopathy, Duchenne muscular dystr...
|
|
WO/2024/106737A1 |
The present invention relates to use of a substance containing a point-mutation FoxM1 protein and peptide for inhibiting the growth, mobility, and invasiveness of cancer cells. In addition, the present invention relates to a use of the s...
|
|
WO/2024/104828A1 |
The present invention relates to an acerola fruit extract. In particular, the invention relates to biological, therapeutic effects and non-therapeutic effects of an acerola fruit extract and compositions comprising the extract.
|
|
WO/2024/107075A1 |
The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a link...
|
|
WO/2024/106878A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising an EZH2 inhibitor and an anti-PD-1 antibody. The pharmaceutical composition was confirmed to show a substantially high th...
|
|
WO/2024/104448A1 |
A pharmaceutical composition of a CDKs inhibitor compound of formula (I), a preparation method for the pharmaceutical composition, and use of the pharmaceutical composition in the preparation of a drug for treating cancer. The provided p...
|
|
WO/2024/107532A1 |
Provided are implantable and biodegradable drug delivery devices capable of delivering an active pharmaceutical ingredient (API) directly to a target pancreatic tumor tissue. The drug delivery devices can include at least two layers. One...
|
|
WO/2024/105553A1 |
The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, R, M, L, W, T, V, Y, K, J, A and y are as described in the Summary of the Invention, therapeu...
|
|
WO/2024/107753A2 |
The present disclosure provides methods of treating or preventing a cancer associated with elevated ASCT2 expression in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a Na+/K+-ATPa...
|
|
WO/2024/107885A1 |
Disclosed herein are nanobody-drug conjugates that can effectively deliver drugs, such as STING agonists. An example conjugate includes an albumin-binding nanobody, a drug, and a linker attaching the nanobody to the drug. Also disclosed ...
|
|
WO/2024/104277A1 |
The present invention relates to a purine derivative that is used as an inhibitor of Bruton's tyrosine kinase (BTK). Specifically, the present invention relates to deuterated (R)-6-amino-9-(1-(but-2-ynyl)pyrrolidin-3-yl)-7-(4-phenoxyph
e...
|
|
WO/2024/106879A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising an EZH2 inhibitor and a BTK inhibitor. The pharmaceutical composition was confirmed to show a substantially high therapeu...
|
|
WO/2024/107923A1 |
A 3-marker metabolite panel (3MetP) comprising or consisting of diacetylspermine, arginine, and creatine riboside, optionally in combination with other panels and/or models, wherein the elevated levels and/or model score classify the pat...
|
|
WO/2024/103440A1 |
Provided are an aminolevulinic acid hydrochloride freeze-dried formulation and a preparation method therefor. With the character, moisture, related substances, and content of the aminolevulinic acid hydrochloride freeze-dried formulation...
|
|
WO/2024/107029A1 |
The present invention relates to a dual gene-transduced T cell using a CTLA-4 variant and a chimeric antigen receptor, and a composition containing same for cancer immunotherapy. According to one aspect, the dual gene-transduced T cell u...
|
|
WO/2024/105205A1 |
This application relates to antibody-2-drug conjugates (A2DCs) which comprise a plurality of kinesin spindle protein inhibitor payloads, optionally having different permeability profiles, which may have advantageous payload release prope...
|
|
WO/2024/105603A1 |
A Ruthenium (II) coordination compound: (III) where n is 0 or 2 and R is selected from the group consisting of: methyl; phenyl; -CH2NH2; -CH2OH; -COOH; an ester group -COOR1, an amide group -CONR2R3, for use as photosensitising agents in...
|
|
WO/2024/107866A1 |
Provided herein are novel exosomal compositions that exhibit cytotoxicity and method of treating cancer that utilize such exosomal compositions.
|
|
WO/2024/103494A1 |
Disclosed are a locally acting androgen receptor antagonist and a use thereof. The androgen receptor antagonist is a compound represented by formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compo...
|
|
WO/2024/107686A1 |
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I' (I') wherein the variables of Formula I' are defined herein. This discl...
|
|
WO/2024/104244A1 |
An oxamide compound, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. Specifically, disclosed is a compound having the structure of formula I, which compound exhibits excellent PRMT5 re...
|
|
WO/2024/104412A1 |
Provided herein are modified IFNα2b proteins and functional fragments thereof. Also provided are polypeptides, such as bi-functional and multi-functional ones, which further include a biological moiety such as an antibody or antigen-bin...
|
|
WO/2024/107928A1 |
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a human subject having a sex hormone-dependent or androgen receptor driven disease or disorder, such as a sex hormone-dependent benign...
|
